ASCO 2021 | ctDNA as a diagnostic, prognostic, and predictive biomarker for lung cancer
Analysis of circulating tumor DNA (ctDNA) has emerged as an effective and promising tool for genomic profiling in non-small cell lung cancer (NSCLC). Bruna Pellini, MD, Moffitt Cancer Center, Tampa, FL, outlines the benefits of using liquid biopsies to detect driver mutations instead of tissue samples. Additionally, lots of research is assessing the predictive ability of ctDNA. Data in solid tumors is suggesting ctDNA levels may correlate with pathological response. Dr Pellini also discusses the potential of ctDNA in lung cancer screening. Several limitations are holding it back, including limited sensitivity in early-stage disease. New assays are under development looking at other markers, such as protein expression and methylation, that may be used in combination with ctDNA genotyping to allow early disease detection. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Bruna Pellini, MD has received research support from Bristol Myers Squibb, advisory board/consultant fees from AstraZeneca and Guidepoint, and speaker honoraria from BioAscend and OncLive.
